Perseus Proteomics Inc. (4882) Other
Market cap
¥3.3B
P/E ratio
Perseus Proteomics develops high-performance antibodies for cancer treatment and drug discovery using proprietary technology from the University of Tokyo.
| 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Return on Assets | - | - | - | - | -57.9 | -2.3 | -1.7 | -7.7 | -9.6 | -12 |
| Return on equity (%) | - | - | - | |||||||
| Employees | 25 | 25 | 20 | 23 | 21 | 19 | 21 | 24 | 25 | 32 |